PE20080842A1 - Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus - Google Patents

Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus

Info

Publication number
PE20080842A1
PE20080842A1 PE2007001237A PE2007001237A PE20080842A1 PE 20080842 A1 PE20080842 A1 PE 20080842A1 PE 2007001237 A PE2007001237 A PE 2007001237A PE 2007001237 A PE2007001237 A PE 2007001237A PE 20080842 A1 PE20080842 A1 PE 20080842A1
Authority
PE
Peru
Prior art keywords
phenyl
inhibitors
useful
trimetoxy
oxazol
Prior art date
Application number
PE2007001237A
Other languages
English (en)
Inventor
Marc Gerspacher
Pascal Furet
Eric Vangrevelinghe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080842(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080842A1 publication Critical patent/PE20080842A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X ES N, CR5; R5 ES HALOGENO, CIANO, HIDROXILO, ALQUILO C1-C7, ENTRE OTROS; R1 ES ARILO, HETEROCICLILO, ENTRE OTROS; R2 ES ARILO O HETEROCICLILO EL CUAL ESTA ENLAZADO POR MEDIO DE UN ATOMO DE CARBONO DEL ANILLO; R3 ES CIANO, HIDROXILO, ALQUILO C1-C7, AMINO, ENTRE OTROS; R4 ES HIDROXILO, AMINO, H. SON COMPUESTOS PREFERIDOS: (7-m-TOLIL-BENZO-OXAZOL-2-IL)-(3,4,5-TRIMETOXI-FENIL)-AMINA; [7-(3-METOXI-FENIL)-BENZO-OXAZOL-2-IL]-(3,4,5-TRIMETOXI-FENIL)-AMINA; [7-(6-METOXI-PIRIDIN-3-IL)-BENZO-OXAZOL-2-IL]-(3,4,5-TRIMETOXI-FENIL)-AMINA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE TIROSINA DE LA CINASA JAK2 UTILES EN EL TRATAMIENTO DE LEUCEMIAS, TROMBOCITOPENIA, MIELOFIBROSIS, ENTRE OTROS
PE2007001237A 2006-09-15 2007-09-13 Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus PE20080842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors

Publications (1)

Publication Number Publication Date
PE20080842A1 true PE20080842A1 (es) 2008-08-11

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001237A PE20080842A1 (es) 2006-09-15 2007-09-13 Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus

Country Status (30)

Country Link
US (1) US8629168B2 (es)
EP (2) EP1900729A1 (es)
JP (1) JP5325105B2 (es)
KR (1) KR20090064389A (es)
CN (1) CN101516860B (es)
AR (1) AR062786A1 (es)
AT (1) ATE532774T1 (es)
AU (1) AU2007296916B2 (es)
BR (1) BRPI0716841A2 (es)
CA (1) CA2660987A1 (es)
CL (1) CL2007002669A1 (es)
CO (1) CO6150142A2 (es)
CR (1) CR10639A (es)
EA (1) EA200900388A1 (es)
ES (1) ES2377148T3 (es)
GT (1) GT200900056A (es)
IL (1) IL196860A0 (es)
MA (1) MA30723B1 (es)
MX (1) MX2009002812A (es)
NO (1) NO20091469L (es)
PA (1) PA8748101A1 (es)
PE (1) PE20080842A1 (es)
PL (1) PL2066647T3 (es)
PT (1) PT2066647E (es)
SM (1) SMP200900023B (es)
TN (1) TN2009000070A1 (es)
TW (1) TW200819444A (es)
UY (1) UY30587A1 (es)
WO (1) WO2008031594A1 (es)
ZA (1) ZA200900477B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
EP2583720A1 (en) * 2008-07-15 2013-04-24 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
EP2323978A1 (en) * 2008-08-12 2011-05-25 Takeda Pharmaceutical Company Limited Amide compound
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
MX2011005621A (es) 2008-11-28 2011-06-20 Kowa Co Derivado de piridin-3-carboxiamida.
JPWO2011078360A1 (ja) 2009-12-24 2013-05-09 武田薬品工業株式会社 アミド化合物
UY33176A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) * 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
CA2938571C (en) 2014-02-03 2020-12-22 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05351B1 (et) * 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007025897A2 (en) * 2005-09-02 2007-03-08 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
KR20090031787A (ko) * 2006-07-21 2009-03-27 노파르티스 아게 Ｊａｋ 키나제 억제제로서의 ２,４-디(아릴아미노)-피리미딘-５-카르복스아미드 화합물

Also Published As

Publication number Publication date
CO6150142A2 (es) 2010-04-20
CA2660987A1 (en) 2008-03-20
CR10639A (es) 2009-07-03
TN2009000070A1 (en) 2010-08-19
CN101516860A (zh) 2009-08-26
US8629168B2 (en) 2014-01-14
TW200819444A (en) 2008-05-01
EA200900388A1 (ru) 2009-08-28
ES2377148T3 (es) 2012-03-22
KR20090064389A (ko) 2009-06-18
ATE532774T1 (de) 2011-11-15
SMP200900023B (it) 2009-07-14
CN101516860B (zh) 2012-06-27
SMAP200900023A (it) 2009-05-11
US20100009978A1 (en) 2010-01-14
JP2010503629A (ja) 2010-02-04
EP1900729A1 (en) 2008-03-19
CL2007002669A1 (es) 2008-05-09
MX2009002812A (es) 2009-03-31
ZA200900477B (en) 2010-01-27
NO20091469L (no) 2009-04-15
BRPI0716841A2 (pt) 2013-10-01
GT200900056A (es) 2011-11-08
IL196860A0 (en) 2009-11-18
EP2066647B1 (en) 2011-11-09
WO2008031594A1 (en) 2008-03-20
PT2066647E (pt) 2012-01-17
AU2007296916A1 (en) 2008-03-20
UY30587A1 (es) 2008-05-02
MA30723B1 (fr) 2009-09-01
EP2066647A1 (en) 2009-06-10
AU2007296916B2 (en) 2011-10-06
PL2066647T3 (pl) 2012-04-30
PA8748101A1 (es) 2009-08-26
AR062786A1 (es) 2008-12-03
JP5325105B2 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
PE20080842A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20080670A1 (es) COMPUESTOS DE 4-METILPIRIDOPIRIMIDINONA COMO INHIBIDORES DE LA FOSFOINOSITIDO 3-QUINASA ALFA (PI3-Ka)
GT200500286A (es) Analogos de anilino-pirimidina
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20040934A1 (es) Derivados de pirimidina como inhibidores selectivos de tirosina quinasas
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
PE20110408A1 (es) Derivados de benzazepina y sus usos como antagonistas de histamina h3
PE20060531A1 (es) Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
PE20060504A1 (es) Derivados de pirimidina en el tratamiento de cancer
ATE455113T1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20080893A1 (es) Triazoles biciclicos como moduladores de la proteina cinasa
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
PE20061417A1 (es) Metodo para sintetizar 3-cianoquinolinas sustituidas y sus intermediarios
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20091833A1 (es) Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion
GT200600107A (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos

Legal Events

Date Code Title Description
FC Refusal